The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 12, pp. 1825-1830. DOI 10.1345/aph.1D262
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D

OBJECTIVO: Repasar la farmacología, la farmacocinética, y el lugar en la terapia de bortezomib.

FUENTE DE DATOS: Una búsqueda de la literatura se llevó a cabo en PubMed/MEDLINE para enero 1985 a mayo 2003. También se usaron extractos de reuniones y bibliografías de artículos identificados.

SELECCIÓN DE ESTUDIOS Y EXTRACCIÓN DE DATOS: Toda información publicada relevante a la actividad clínica de bortezomib en mieloma múltiple (MM) fue considerada. Todos los estudios clínicos con énfasis en estudios de Fase II fueron seleccionados.

SÍNTESIS DE DATOS: La terapia actual para MM rinde respuestas significativas aunque temporales. Bortezomib es un agente anticáncer novedoso con actividad significativa en MM en relapso y refractorio.

CONCLUSIONES: Aunque es temprano en los datos de estudios clínicos, bortezomib ofrece una modalidad terapeútica nueva para pacientes con MM que de otra manera tendrían muy pocas opciones.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. A. Luster, J. A. Carrell, K. McCormick, D. Sun, and R. Humphreys
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Mol. Cancer Ther., February 1, 2009; 8(2): 292 - 302.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. A. Poff, C. T. Allen, B. Traughber, A. Colunga, J. Xie, Z. Chen, B. J. Wood, C. Van Waes, K. C. P. Li, and V. Frenkel
Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib
Radiology, August 1, 2008; 248(2): 485 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. M. Bailey, D. E. Abbott, N. V. Margaryan, Z. Khalkhali-Ellis, and M. J. C. Hendrix
Interferon Regulatory Factor 6 Promotes Cell Cycle Arrest and Is Regulated by the Proteasome in a Cell Cycle-Dependent Manner
Mol. Cell. Biol., April 1, 2008; 28(7): 2235 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood, February 1, 2008; 111(3): 1309 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis
Clin. Cancer Res., June 1, 2007; 13(11): 3403 - 3412.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. R. Chade, J. Herrmann, X. Zhu, J. D. Krier, A. Lerman, and L. O. Lerman
Effects of Proteasome Inhibition on the Kidney in Experimental Hypercholesterolemia
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1005 - 1012.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.